ArticleJournal of the European Academy of Dermatology and Venereology : JEADV2026
Dual impact of smoking cessation and post-cessation weight change on psoriasis.
Article in Journal of the European Academy of Dermatology and Venereology : JEADV, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Smoking, alcohol consumption, and psoriasis risk: a systematic review and dose-response meta-analysis of observational studies.Frontiers in public health · 2026Pooled it
- Methodological considerations for smoking cessation, weight change, and psoriasis.Journal of the European Academy of Dermatology and Venereology : JEADV · 2026Article
- Dual impact of smoking cessation and post-cessation weight change on psoriasis.Journal of the European Academy of Dermatology and Venereology : JEADV · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundThe impact of post-cessation weight changes on the preventive effect of smoking cessation on psoriasis remains unknown.
objectivesTo examine the association between smoking cessation, subsequent weight changes measured using body mass index (BMI), risks of psoriasis vulgaris (PsV), palmoplantar pustulosis (PPP) and generalized pustular psoriasis (GPP).
methodsThis nationwide cohort study, performed using the Korean National Health Insurance Service database, included 5,470,955 participants who underwent two consecutive biennial health screenings from 2004 to 2005 and 2006 to 2007. Data on changes in smoking habits and BMI status were obtained from these health screenings. The Cox proportional hazards model was utilized to estimate the risk of developing psoriasis based on changes in smoking habits and weight status.
resultsOver 73.7 million person-years, 63,538 cases of psoriasis were identified, including 49,157 PsV, 9291 PPP and 2298 GPP cases. Smoking quitters without weight changes (adjusted hazard ratio [aHR] 0.85; 95% confidence interval [CI] 0.79-0.92) and those with weight loss (aHR 0.88; 95% CI 0.79-0.97) showed a lower risk of psoriasis, including PsV and PPP, compared to sustained smokers. However, post-cessation weight gain attenuated the benefits of smoking cessation, particularly for PsV. Nevertheless, the protective effect of smoking cessation on PPP remained substantial even in quitters with weight gain (aHR 0.67; 95% CI 0.57-0.79). In sensitivity analyses considering the time-varying characteristics of smoking status and weight changes and examining the long-term effects of smoking cessation, a notable decrease in the risk of psoriasis, including PsV and PPP, was identified regardless of post-cessation weight change.
conclusionsDespite post-cessation weight gain, smoking cessation should be encouraged to prevent psoriasis, and weight management is recommended to maximize the health benefits of quitting smoking for psoriasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.